U.S. Markets close in 55 mins

Regeneron Cancer Drug Gives Anxious Investors Hope

Josh Nathan-Kazis

Anxious investors in the biotech firm (REGN)(ticker: REGN), shares of which fell early this month after its first-quarter earnings missed Wall Street expectations, woke up to happy news this morning. Regeneron has tanked over the past three months, down 27% since mid-February. Shares haven’t budged on Regeneron’s Libtayo news.